AstraZeneca says the Department of Justice is ending its investigation into PLATO, a clinical trial with its heart drug Brilinta, and is not planning any further action. It began investigating the PLATO trial, which studied more than 18,000 patients in 43 countries, last October after suspicions were raised that the clinical trial numbers may have been manipulated. In a statement, AstraZeneca CEO Pascal Soriot said, "We have always had absolute confidence in the integrity of the PLATO trial and we are proud of the important benefit Brilinta offers to patients around the world suffering from acute coronary syndrome."

More from Video

The Demise of the Great American Supermarket (Watch!)

The Demise of the Great American Supermarket (Watch!)

China to Slash Automobile Tariffs and 4 Other Stories You Must Know Tuesday

China to Slash Automobile Tariffs and 4 Other Stories You Must Know Tuesday

Listen: Smart Technologies That Could Lure Millennials Back to Motorcycle Riding

Listen: Smart Technologies That Could Lure Millennials Back to Motorcycle Riding

60 Seconds: What is the Volcker Rule and How Does it Affect Your Portfolio?

60 Seconds: What is the Volcker Rule and How Does it Affect Your Portfolio?

Video: Here's How Global Stocks Can Boost Your Portfolio

Video: Here's How Global Stocks Can Boost Your Portfolio